For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024.

Studies have linked early deaths and asthma exacerbations to chronic exposure to particulate matter in wildfire smoke.

Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...